Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy.
A double-blind placebo-controlled between-patient study was carried out to assess the effects of oxiracetam (CGP 21690E) on memory function in patients with epilepsy. During a 12-week period, either oxiracetam (800 mg t.i.d.) or placebo was given to 30 patients. Twenty-four of the patients had a partial epilepsy. Most patients were on monotherapy carbamazepine. Effect of oxiracetam on memory and related cognitive functions were assessed, using a computerized neuropsychological testing method, while concomitant electrophysiological changes were investigated with routine EEG registration, power spectrum analysis and auditory evoked event-related potentials (P300). Subjective evaluation of well-being was quantified with a mood rating scale. The results did not show any meaningful changes in memory function. This finding is in line with the subjective patient reports and the P300 measures.
Aldenkamp
A P
AP
Institute voor Epilepsiebestrijding; Meer & Bosch/De Cruquiushoeve, Heemstede, Nederland.
van Wieringen
A
A
Alpherts
W C
WC
van Emde Boas
W
W
Haverkort
H A
HA
de Vries
J
J
Meinardi
H
H
D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects; D003071:Cognition / Q000187:drug effects; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000150:complications* / Q000523:psychology; D005072:Evoked Potentials, Auditory / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D008606:Mental Processes / Q000502:physiology; D008875:Middle Aged; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*
D011619:Psychotropic Drugs; D011759:Pyrrolidines; C040619:oxiracetam